Targeting the molecular defect in BRCA-deficient tumors for cancer therapy.

Cancer cell ·Vol. 16 ·No. 2 ·2009-08-21

Venkitaraman Ashok R

Abstract

Targeted therapies exploiting specific molecular defects in cancer cells promise to overcome roadblocks in the development of effective anticancer drugs. A recent report in the New England Journal of Medicine on the early clinical evaluation of Olaparib in cancers lacking the BRCA1 or BRCA2 genes exemplifies this promising new trend.

Article Info

Journal

Cancer cell

Abbr.

Cancer Cell

ISSN

1535-6108

DOI

10.1016/j.ccr.2009.07.011

Published

2009-08-21

Indexed

2009-08-03

Updated

2016-11-22

Language

English

Country/Region

United States

NLM ID

101130617

External Links

PubMed source DOI: 10.1016/j.ccr.2009.07.011 View journal details

Analysis Services

Targeting the molecular defect in BRCA-deficient tumors for cancer therapy.

Contact

WeChat Official Account